Microbiology and Infectious Diseases Research

Active

Assistance listing
93.856
Agency
Grant awards
16,229 $6,981,765,868 in federal obligations

Program facts

Also known as
PLEASE SEE PROGRAM 93.855; Allergy and Infectious Diseases Research NO FUNDING WILL BE REPORTED UNDER 93.856
Assistance types
  • Project Grant
  • Block Grant
  • Cooperative Agreement
Eligible applicants
  • Individual/Family
  • State (includes District of Columbia, public institutions of higher education and hospitals)
  • Local (includes State-designated lndian Tribes, excludes institutions of higher education and hospitals
  • Public nonprofit institution/organization (includes institutions of higher education and hospitals)
  • Private nonprofit institution/organization (includes institutions of higher education and hospitals)
Beneficiaries
  • Profit organization
  • Private nonprofit institution/organization
  • Student/Trainee
  • Scientist/Researchers
  • State
  • Local
  • Public nonprofit institution/organization
Treasury account
  • 75-0885-0-1-552
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The National Institutes of Health is operating CFDA 93.856, Microbiology and Infectious Diseases Research, but has formally redirected all funding activity to CFDA 93.855 (Allergy and Infectious Diseases Research), where no awards are being reported under 93.856 as of the most recent portfolio snapshot dated August 2017.

The program historically funded basic and translational research on bacterial, viral, fungal, and parasitic pathogens. Representative recent awards included investigations of biofilm formation in Bordetella pertussis ($426,250), microparticle-based treatment for visceral leishmaniasis ($402,491), engineering of viral polymerase fidelity to improve live-attenuated vaccines ($428,726), and structural studies of hepatitis B virus ribonuclease H ($151,367). The portfolio also supported diagnostic development, vaccine design, and mechanism-of-action studies across a range of pathogens including E. coli, Legionella, Borrelia burgdorferi, Epstein-Barr virus, Toxoplasma gondii, Cryptococcus neoformans, and malaria parasites.

Awards were predominantly Project Grants (99 percent of 16,229 total awards), with smaller shares of Block Grants (1 percent) and Cooperative Agreements (less than 1 percent). The National Institutes of Health accounted for 16,205 awards and $6.95 billion in federal dollars obligated—99.9 percent of the program's $6.98 billion total. Typical individual award magnitudes ranged from roughly $150,000 to $450,000 for Project Grants; one Cooperative Agreement (U19AI091173) reached $16.3 million for biodosimetry research related to radiation incidents.

The most recent grant award was made on August 1, 2017. Award activity has been minimal in recent years: the portfolio recorded only 2 awards in 2012, 1 in 2013, 1 in 2015, 21 in 2016, and 1 in 2017. The program began awarding in 1985.

No current grant opportunities are open under CFDA 93.856. Applicants seeking to pursue infectious disease research funding should consult CFDA 93.855 and recent NIH solicitations such as the Ecology and Evolution of Infectious Diseases program (19-592, due November 2020) or small business programs under the 2019-02 SBIR/STTR omnibus announcements (PA-19-272, PA-19-273, due July 2020).

Objective and description

Objective

PLEASE SEE PROGRAM 93.855; Allergy and Infectious Diseases Research NO FUNDING WILL BE REPORTED UNDER 93.856

Eligibility

Applicant eligibility

Universities, colleges, hospitals, laboratories and other public or private nonprofit domestic institutions, including State and local units of government. Individuals are eligible to make application for grant support of research by a named principal investigator or a research career development candidate. For-profit organizations are also eligible, with the exception of NRSA. Individual NRSA awardees must be nominated and sponsored by a public or nonprofit private institution having staff and facilities appropriate to the proposed research training program. All NRSA awardees must be citizens or have been admitted to the United States for permanent residence. To be eligible, predoctoral candidates must have completed the baccalaureate degree and postdoctoral candidates must have a professional or scientific degree (M.D., Ph.D., D.D.S., D.O., D.V.M., Sc.D., D.Eng.), or must have an equivalent domestic or foreign degree. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is being proposed and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. or its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which researches proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary eligibility

Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.

Credentials and documentation

Research grant applicants must define the objectives, methodology, and facilities for the program, and must present the program director's competence and scientific interest. For SBIR and STTR grants, applicant organization (small business concern) must present in a research plan an idea that has potential for commercialization and furnish evidence that scientific competence, experimental methods, facilities, equipment, and funds requested are appropriate to carry out the plan. Grant forms PHS 6246-1 and PHS 6246-2 are used to apply for SBIR Phase I and Phase II, respectively. Grant forms PHS 6246-3 and PHS 6246-4 are used to apply for STTR Phase I and Phase II, respectively. Applicants for Individual NRSAs must include their academic record, research experience, citizenship, institutional sponsorship, and the proposed area and plan of training in their applications. The applicant for an Institutional NRSA must specify the objectives, methodology, and resources for the research training program, the qualifications and experience of directing staff, the criteria to be used in selecting individuals for award, and a detailed budget and justification for the amount of grant funds requested. For-profit organizations' costs are determined in accordance with Subpart 31.2 of the Federal Acquisition Regulations. For other grantees, costs will be determined by HHS Regulations 45 CFR, Part 74, Subpart Q.

Uses of assistance

PLEASE SEE PROGRAM 93.855; Allergy and Infectious Diseases Research NO FUNDING WILL BE REPORTED UNDER 93.856

Length and time phasing of assistance

Research grant project periods average 4 years; these may not be extended beyond 7 years. (Project periods are generally composed of 1-year budget periods.) SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.

How to apply

Application procedure

PLEASE SEE PROGRAM 93.855; Allergy and Infectious Diseases Research NO FUNDING WILL BE REPORTED UNDER 93.856

Criteria for selecting proposals

See relevant program announcements.

Award procedure

PLEASE SEE PROGRAM 93.855; Allergy and Infectious Diseases Research NO FUNDING WILL BE REPORTED UNDER 93.856

Time to approval or disapproval

PLEASE SEE PROGRAM 93.855; Allergy and Infectious Diseases Research NO FUNDING WILL BE REPORTED UNDER 93.856

Renewals

Renewals of research grant support are by competitive application and review. The competitive application may request support for a segmental period of up to 5 years.

Appeals

A principal investigator may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. Final decisions on unresolved appeals are made with the advice of the National Advisory Allergy and Infectious Diseases Council.

Grant opportunities

Opportunity Status Posted Applications due
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required) RFA-HL-20-030 Closed
Ecology and Evolution of Infectious Diseases 19-592 Closed
PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required PA-19-273 Closed
PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed PA-19-272 Closed
PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required PA-19-271 Closed
PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed PA-19-270 Closed
Building Interdisciplinary Research Careers in Women's Health (BIRCWH); K12 Clinical Trial Optional RFA-OD-19-020 Closed
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) PAR-19-274 Closed
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) PA-18-906 Closed
Ecology and Evolution of Infectious Diseases 18-581 Closed
Regenerative Medicine Innovation Projects (RMIP) (UT2 - Clinical Trial Not Allowed) RFA-HL-18-033 Closed
Regenerative Medicine Innovation Projects (RMIP) (U44 - Clinical Trial Not Allowed) RFA-HL-18-035 Closed
Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Studies (Collaborative U01 Clinical Trial Not Allowed) RFA-HL-18-030 Closed
Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required) RFA-HL-18-031 Closed
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) PAR-18-840 Closed
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) PA-18-648 Closed
Opportunities for Collaborative Research at the NIH Clinical Center (U01 - Clinical Trial Optional) PAR-18-646 Closed
Successor-in-Interest (Type 6 Parent Clinical Trial Optional) PA-18-589 Closed
Change of Grantee Organization (Type 7 Parent Clinical Trial Optional) PA-18-590 Closed
Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed ) PA-18-592 Closed
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional) PA-18-591 Closed
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) PA-18-586 Closed
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) PA-18-575 Closed
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) PA-18-574 Closed
Academic Research Enhancement Award (Parent R15 Clinical Trial Not Allowed) PA-18-504 Closed
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-18-484 Closed
Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional) PA-18-048 Closed
Trophoblast Differentiation and Function (R21 Clinical Trial Optional) PA-18-047 Closed
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) PAR-18-206 Closed
The Health of Sexual and Gender Minority (SGM) Populations (R21 Clinical Trial Optional) PA-18-040 Closed
The Health of Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) PA-18-037 Closed
The Health of Sexual and Gender Minority (SGM) Populations (R03 Clinical Trial Optional) PA-18-054 Closed
The Health of Sexual and Gender Minority (SGM) Populations (R15 Clinical Trial Optional) PA-18-210 Closed
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) PAR-18-007 Closed
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) PAR-18-017 Closed
Research on Transgender Health (R01) PA-17-478 Closed
Research on Transgender Health (R21) PA-17-477 Closed
Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03) PAR-17-439 Closed
Assay development and screening for discovery of chemical probes or therapeutic agents (R01) PAR-17-438 Closed
Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) PAR-17-333 Closed
NIAID Physician-Scientist Pathway to Independence Award (K99/R00) PAR-17-329 Closed
Small Grants on Primary Immunodeficiency Diseases (R03) PAR-17-332 Closed
Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03) PA-17-324 Closed
Administrative Supplements for Research on Dietary Supplements (Admin Supp) PA-17-307 Closed
Optimizing HIV Phylodynamics to Target and Interrogate Clusters (OPTICs) (R21) PA-17-306 Closed
Imaging the Persistent HIV Reservoir (R01) PA-17-305 Closed
PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) PA-17-303 Closed
PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) PA-17-302 Closed
Partnerships for Development of Clinically Useful Diagnostics for Antimicrobial-Resistant Bacteria (R01) RFA-AI-17-014 Closed
Partnerships for the Development of Vaccines and Immunophrophylactics Targeting Multiple Antimicrobial-Resistant Bacteria (R01) RFA-AI-17-017 Closed
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Latest 10 of 16,229 listed here. See the rest on GovTribe.

Top recipients by federal obligations

Rank Recipient Federal obligations Share
1 Trustees Of Dartmouth College $16,700,752 <1%
2 Duke University $4,488,680 <1%
3 Monogram Biosciences, Inc. $3,951,391 <1%
4 Panthera Biopharma, LLC $3,769,979 <1%
5 Trustees Of Tufts College $3,750,000 <1%
6 University Of Illinois $3,638,813 <1%
7 Microbiotix, Inc. $2,625,784 <1%
8 George Mason University $2,475,000 <1%
9 The Washington University $2,363,675 <1%

9 of 171 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2021 $4,081,343
FY2020 $2,869,781
FY2019 $1,498,428
FY2018 $3,830,552
FY2017 $6,252,893
FY2016 $8,513,811
FY2015 $829,375
FY2014 $4,265,187
FY2013 $4,202,389
FY2012 $4,696,432
FY2011 $5,352,332
FY2010 $5,959,113
FY2009 $15,562,825
FY2008 $15,140,760
FY2007 $102,298,109
FY2006 $84,473,312
FY2005 $1,727,080,296
FY2004 $1,637,329,595
FY2003 $1,821,236,689
FY2002 $1,004,420,836
FY2001 $568,514,230
Show all 21

Quick answers

What is Assistance Listing 93.856?

Assistance Listing 93.856 is Microbiology and Infectious Diseases Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Microbiology and Infectious Diseases Research?

Its CFDA number is 93.856: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.856 awarded?

16,229 grant awards under 93.856 have obligated $6,981,765,868 in federal funds to 171 recipients.

Who receives the most funding from 93.856?

The recipients obligated the most under Microbiology and Infectious Diseases Research are Trustees Of Dartmouth College ($16,700,752), Duke University ($4,488,680) and Monogram Biosciences, Inc. ($3,951,391).

Are there open grant opportunities under 93.856?

None of the latest 50 opportunities under 93.856 is open now. The latest, Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required), was posted on August 14, 2019.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program